Our bodies are made of billions of cells. However, the cells in our bodies are far outnumbered by the bacteria that cover our skin and inhabit our gut. These bacteria are now increasingly recognized to have an important role in maintaining our health. For example, skin bacteria help protect us from more dangerous bacteria that could invade us. Gut bacteria help digest our food. There are suggestions that changes in these bacteria, particularly those in the gut, might play a role in several diseases.
Swedish MS Center represented at Congress of the European Committee for the Treatment and Research in MS
The 29th Congress of the European Committee for the Treatment and Research in MS (ECTRIMS) and the 18th Annual Conference on Rehabilitation in MS (RIMS) were held on October 2-5 in Copenhagen, Denmark. These two meetings are the largest scientific meetings on MS and rehabilitation in MS, with over 8,000 people attending this year.
The MS Center at Swedish was well-represented with five people attending. The meeting consisted of educational courses, symposia and scientific research presentations. The scientific presentations included over 1200 posters describing recent research in MS. There were also over 200 oral scientific research presentations. Upcoming blog posts will cover some of the reports that were of most interest to us.
October 7th was Trigeminal Neuralgia Awareness Day and for many reading or hearing the stories, like the story on CNN.com, this condition may not be familiar. However, for those suffering from trigeminal neuralgia, every day can be challenging.
Facial pain in Trigeminal Neuralgia is characterized by episodes of intense pain lasting from a few seconds to hours at a time. The attacks are often described as electric shock like, burning, pressing, crushing, or shooting pain. Patients describe areas on the face as sensitive to the point that even a gentle breeze of wind can trigger an episode of pain.
Once diagnosed, trigeminal neuralgia can be treated with ...
It’s our pleasure to announce that Buddy Hayes will be coming to the MS Center on October 21! Buddy is a motivational speaker who’s passionate about educating the public on the daily challenges that people with disabilities face and how they overcome them. She is a retired certified therapeutic recreation specialist as well as a veteran of the US Army.
Buddy has been living with multiple sclerosis for many years and she’s turned her diagnosis into an opportunity to change the way that the world perceives people with disabilities. Buddy has shown that she is not only an inspirational speaker, but she’s also unafraid to take on any challenge. Just a few of her many accomplishments include skiing, rock climbing, surfing, scuba diving, and winning the title of Ms. Wheelchair Virginia 2007-2008. One of the many ways that Buddy takes on challenges is with the help of her service dog, Stanford.
On October 21, Buddy (and Stanford) will be coming to the MS Center to talk about what a service dog is, how to obtain one, and how they can change a life forever.
We welcome all who’d like to attend Buddy’s presentation:
October 21st 1:00-2:00 pm
Hedreen Wellness Studio, MS Center
Jefferson Tower, Level A
The Swedish Radiosurgery Center is the lead site in a national multi-institutional study evaluating CyberKnife for treating men with intermediate-risk prostate cancer (clinical stage 2). As the principal investigator of this study, I reported on the quality of life outcomes at the annual meeting of American Society of Radiation Oncology.
We now know that in low-risk prostate cancer patients (stage 1), active surveillance is a safe option. But men with intermediate-risk cancer have a significant risk of dying of their disease, so intervention is necessary. Conventional treatments (surgery, radioactive seed implants and external beam radiotherapy) can adversely affect patients’ quality of life. We sought to determine if the unprecedented accuracy of CyberKnife treatment would translate into improvement in these patients’ quality of life.
We treated ..
On September 17, the European Commission, the European equivalent of the US Food and Drug Administration (FDA), approved the release of alemtuzumab (Lemtrada™.)
Alemtuzumab is an intravenous monoclonal antibody that selectively reduces circulating T lymphocytes, which are thought to be involved in inflammation in multiple sclerosis (MS). This reduction is followed by repopulation of T and B cells over time. It is administered on five consecutive days in the first year of therapy, followed by three consecutive days 12 months later.
Swedish Neuroscience Institute was involved in Care-MS II, one of the pivotal Phase III studies in which MS patients who had relapsed on other therapies were randomized to either alemtuzumab or interferon beta-1a. The drug was found to be significantly ...
The Swedish S’myelin Babes, Swedish’s Bike MS team, raised more than $46,000 this year. The annual event raises funds for multiple sclerosis research and local programs to support people living with the disease.
Check out a few photos captured by Dr. Lily JungHenson from this year’s event: